$UNCY Cashflow Statement | Understand Stock

$UNCY

$3.61 +$0.03 (0.84%) Close

$UNCY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
R&D expense for issuance of common stock for anti-dilution clause
G&A expense for issuance of common stock
Convertible debt discount amortization
Stock-based compensation expense
Change in fair value of warrant liability
Amortization of operating lease right of use asset
Convertible debt non-cash interest
Gain on extinguishment of debt
Deferred compensation to CEO
Loss on debt conversion
Prepaid expense and other current assets

Changes in assets and liabilities:
Prepaid expense and other current assets
Accounts payable and accrued liabilities
Operating lease liability
Related party service fee payable

Net cash used in operating activities
Cash flows from investing activities
Purchases of property, plant and equipment
Purchases of marketable securities
Purchases of property and equipment

Net cash used in investing activities
Payments on financed insurance policies
Proceeds from exercise of options
Issuance of common stock for cash, net of issuance costs
Cash flows from financing activities
Net proceeds from initial public offering
Issuance of common stock for cash, net of issuance costs
Proceeds from loan from stockholder
Proceeds from convertible notes
Repayment of loan from stockholder
Gross proceeds from secondary public offering
Commissions paid on secondary public offering
Deferred cost of at the market offering
Proceeds from issuance of Series A-1 preferred stock and warrants
Issuance costs related to Series A-1 preferred stock and warrants
Payments on financed insurance policies
Issuance costs related to issuance of Series B-1 preferred stock
Proceeds from issuance of Series B-1 preferred stock
Proceeds from exercise of warrants
Dividends on preferred stock

Net cash provided by financing activities
Net increase (decrease) in cash
Net increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period
Supplemental cash flow information
Deferred preclinical charges included in prepaid expenses and other current assets
Issuance of Series B-2 preferred stock and common stock upon conversion of Series B-1 preferred stock
Deferred insurance charges included in prepaid expenses and other current assets
Issuance of Series A-2 preferred stock and common stock upon conversion of Series A-1 preferred stock
Accrued dividends on preferred stock
Fair value of warrants issued in connection with the issuance of preferred stock
Cash paid for interest

Comments